Well this is one good news and an A+ for the FDA.. Fast Track program is what we need. This is indeed a very good news.
From the article it seems promising but i couldnt understand whether it is used to reverse fatty liver? Fibrosis? Or both?
today announced that the U.S. Food and Drug Administration (FDA) has granted GR-MD-O2 (galactoarabino-rhamnogalacturonate) ""Fast Track designation"" for non-alcoholic steatohepatitis (NASH).
The FDA's Fast Track program is designed to expedite the review of new drugs that are intended to treat serious or life-threatening conditions and demonstrate the potential to address unmet medical needs.
gilead gs-9620 and arc 520 should and must proceed under this option "FDA fast track program".